AGP Wins Silver Award at the SAFA Best Presented Annual Report Awards 2024

AGP Wins 1st Position in Pharmaceutical Category at BCSR Awards 2024 — for the Second Consecutive Year!

AGP Celebrates Dual Recognition at the 8th Pakistan Pharma Summit & PESA Awards 2025

AGP Receives the 22nd Annual Environment Excellence Award 2025

AGP Wins GDEIB Awards in Nine Categories

AGP x TrashIt Sustainability Training

AGP x Cyber Security Awareness Training

AGP x Cancer Foundation Hospital: Breast Cancer Awareness Session

AGP Visits Karachi Down Syndrome Program (KDSP)

Diwali Celebration at AGP: Honoring Diversity, Culture & Togetherness

AGP Limited Secures 1st Position at BCSR Awards 2023

AGP collaborates with Childlife Foundation on Children’s Day 2023

AGP Launched Peridots – A Thanda Solution to Acidity, Gas and Indigestion

AGP secures 2nd Position at BCR Awards 2022

AGP wins Top Exporter Award at 6th PPMA Summit

AGP sponsors KDSP Carnival 2023

AGP bags big win at GDEIB Awards 2023

AGP continues partnership with IBA

AGP continues collaboration with TCF

AGP joins hands with SKMF

AGP continues partnership with ACF

AGP conducts Allergy Awareness Session At Pak Turk Maarif

Gong-Ringing Ceremony of AGP at PSX

Product List

Analar

Generic:

Tizanidine

 

Therapeutic Class:

Muscle Relaxants, Central

 

Composition:

Each tablet contains 2 mg
tizanidine base.

 

Description:

Analar is a centrally acting α2-adrenergic agonist.

 

Indications:

  • Painful muscle spasms associated with static and functional disorders of the spine (cervical and lumber syndromes) 
  • Painful muscle spasms following surgery e.g. for herniated intervertebral disc or osteoarthritis of the hip 
  • Spasticity due to neurological disorders e.g. degenerative spinal cord diseases, chronic myelopathy, multiple sclerosis, cerebral palsy and cerebrovascular accidents.
 

Dosage:

Children:
The use of Analar in children is not recommended.Adults:
For relief of painful muscle spasms:The dose of Analar is 2 to 4 mg thrice daily. In severe conditions, an extra dose of 2 or 4 mg may be taken at night.For spasticity due to neurological disorders:
The initial daily dose may be increased stepwise at half-weekly or weekly intervals by 2 to 4 mg but initially it should not exceed 6 mg given in 3 divided doses. The optimum therapeutic response is achieved when daily dose is between 12 and 24 mg, administered in 3 to 4 divided doses. The total daily dose should not exceed 36 mg. 

Presentations:

Analar 2 mg tablet is availble in pack of 10’s